Published • loading... • Updated
Factbox-US Drugmakers Turn to China for Licensing Deals
The deal gives Merck access to a preclinical oral drug targeting a common cancer mutation as it seeks to refill its pipeline before Keytruda patent losses.
- On Monday, Merck agreed to pay Chinese biotech SciBrunch Therapeutics up to $2.13 billion for global rights to develop and sell SPR2015, an experimental cancer drug targeting KRAS G12D-mutant cancers.
- This acquisition expands Merck's cancer drug pipeline as the company prepares for patent expirations on Keytruda, its top-selling immunotherapy, later this decade.
- SciBrunch will receive $400 million upfront and is eligible for up to $1.73 billion in potential milestone payments under the licensing agreement.
- The transaction will result in a pre-tax charge of $400 million, or about 13 cents per share, affecting Merck's third-quarter 2026 results.
- Chinese biotechs often retain domestic rights while licensing drugs overseas, securing upfront payments and royalties to fund further development.
Insights by Ground AI
12 Articles
12 Articles
Factbox-US drugmakers turn to China for licensing deals
Sept 28 (Reuters) - Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines. Chinese biote...
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Regional Media News
Sept 28 (Reuters) - Merck said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, manufacture and sell an experimental cancer treatment. The deal underscores Merck's efforts to broaden its cancer drug [...]
Coverage Details
Total News Sources12
Leaning Left0Leaning Right2Center1Last UpdatedBias Distribution67% Right
Bias Distribution
- 67% of the sources lean Right
67% Right
C 33%
R 67%
Factuality
To view factuality data please Upgrade to Premium
